Cargando…

Texture analysis of (125)I-A5B7 anti-CEA antibody SPECT differentiates metastatic colorectal cancer model phenotypes and anti-vascular therapy response

BACKGROUND: We aimed to test the ability of texture analysis to differentiate the spatial heterogeneity of (125)I-A5B7 anti-carcinoembryonic antigen antibody distribution by nano-single photon emission computed tomography (SPECT) in well-differentiated (SW1222) and poorly differentiated (LS174T) hep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rajkumar, V, Goh, V, Siddique, M, Robson, M, Boxer, G, Pedley, R B, Cook, G J R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4580400/ https://www.ncbi.nlm.nih.gov/pubmed/25989271 http://dx.doi.org/10.1038/bjc.2015.166

Ejemplares similares

Fractionated (131)I anti-CEA radioimmunotherapy: effects on xenograft tumour growth and haematological toxicity in mice
por: Violet, J A, et al.
Publicado: (2008)

Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models
por: El-Emir, E, et al.
Publicado: (2007)

PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models
por: Dredge, K, et al.
Publicado: (2011)

Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer
por: Augustine, T A, et al.
Publicado: (2015)

Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody
por: Osada, T, et al.
Publicado: (2010)

Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs
por: Gelardi, T, et al.
Publicado: (2008)

Acute changes in liver tumour perfusion measured non-invasively with arterial spin labelling
por: Johnson, S Peter, et al.
Publicado: (2016)

The effect of serum CEA on the distribution and clearance of anti-CEA antibody in a pancreatic tumour xenograft model.
por: Pedley, R. B., et al.
Publicado: (1989)

Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours
por: Gelardi, T, et al.
Publicado: (2010)

Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs
por: Bianco, R, et al.
Publicado: (2008)

Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells
por: Johnson, N, et al.
Publicado: (2010)

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
por: Rowland, A, et al.
Publicado: (2015)

Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations
por: Bramley, M, et al.
Publicado: (2006)

Prognostic role of ERBB2, MET and VEGFA expression in metastatic colorectal cancer patients treated with anti-EGFR antibodies
por: Takahashi, Naoki, et al.
Publicado: (2016)

In vitro evaluation of cancer-specific NF-κB-CEA enhancer–promoter system for 5-fluorouracil prodrug gene therapy in colon cancer cell lines
por: Guo, X, et al.
Publicado: (2007)

Small molecule MIRA-1 induces in vitro and in vivo anti-myeloma activity and synergizes with current anti-myeloma agents
por: Saha, M N, et al.
Publicado: (2014)

Synthetic phosphoethanolamine has in vitro and in vivo anti-leukemia effects
por: Ferreira, A K, et al.
Publicado: (2013)

The HIF-pathway inhibitor NSC-134754 induces metabolic changes and anti-tumour activity while maintaining vascular function
por: Baker, L C J, et al.
Publicado: (2012)

Prediction of tumour response induced by chemotherapy using modelling of CA-125 kinetics in recurrent ovarian cancer patients
por: Wilbaux, M, et al.
Publicado: (2014)

The role of zinc in the anti-tumour and anti-cachectic activity of D-myo-inositol 1,2,6-triphosphate
por: Russell, S T, et al.
Publicado: (2010)

Predicting breast cancer response to neoadjuvant chemotherapy using pretreatment diffuse optical spectroscopic texture analysis
por: Tran, William T, et al.
Publicado: (2017)

Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases
por: Parakh, Sagun, et al.
Publicado: (2017)

Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma
por: Gammons, M V, et al.
Publicado: (2014)

RANK/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIs
por: Beuselinck, B, et al.
Publicado: (2015)

Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity
por: den Brok, M H M G M, et al.
Publicado: (2006)

Induction of thrombospondin-1 partially mediates the anti-angiogenic activity of dexrazoxane
por: Maloney, S L, et al.
Publicado: (2009)

Anti-HER-2 DNA vaccine protects Syrian hamsters against squamous cell carcinomas
por: Berta, G N, et al.
Publicado: (2005)

Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients
por: Montagut, C, et al.
Publicado: (2010)

The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers
por: Newman, S P, et al.
Publicado: (2007)

Selective cyclooxygenase-2 silencing mediated by engineered E. coli and RNA interference induces anti-tumour effects in human colon cancer cells
por: Strillacci, A, et al.
Publicado: (2010)

Normal tissues toxicities triggered by combined anti-angiogenic and radiation therapies: hurdles might be ahead
por: Mangoni, M, et al.
Publicado: (2012)

Decomposition of spontaneous fluctuations in tumour oxygenation using BOLD MRI and independent component analysis
por: Gonçalves, Miguel R, et al.
Publicado: (2015)

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models
por: Holt, S V, et al.
Publicado: (2012)

Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms
por: Gujar, S A, et al.
Publicado: (2014)

Enzastaurin has anti-tumour effects in lung cancers with overexpressed JAK pathway molecules
por: Shimokawa, T, et al.
Publicado: (2012)

Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism
por: Cambien, B, et al.
Publicado: (2009)

Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy
por: Tazzari, M, et al.
Publicado: (2014)

Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo
por: Andersson, Y, et al.
Publicado: (2009)

Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells
por: Ioannou, N, et al.
Publicado: (2011)

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma
por: Carlino, M S, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_hcrncol3q44bpkv7tt6pil72fk